Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily develo** and was approved for the …

Background Hepatocellular carcinoma (HCC) is one of the most common malignancies
globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC …

Background and aims Accumulating evidence suggests that the primary and acquired
resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple …

Background Drug resistance to sorafenib greatly limited the benefits of treatment in patients
with hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) participate in the development …

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the
leading causes of cancer-related death worldwide. Advanced HCC displays strong …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths
worldwide. HCC initiation, progression, and therapy failure are all influenced by various …

The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still
facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival …

Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem
cell pluripotency and differentiation to trigger cell proliferation, organ development, and …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, and it
usually occurs following chronic liver disease. Although some progress has been made in …